BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 28257320)

  • 1. Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma.
    Roman-Gonzalez A; Zhou S; Ayala-Ramirez M; Shen C; Waguespack SG; Habra MA; Karam JA; Perrier N; Wood CG; Jimenez C
    Ann Surg; 2018 Jul; 268(1):172-178. PubMed ID: 28257320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years.
    Hamidi O; Young WF; Iñiguez-Ariza NM; Kittah NE; Gruber L; Bancos C; Tamhane S; Bancos I
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3296-3305. PubMed ID: 28605453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma.
    Assadipour Y; Sadowski SM; Alimchandani M; Quezado M; Steinberg SM; Nilubol N; Patel D; Prodanov T; Pacak K; Kebebew E
    Surgery; 2017 Jan; 161(1):230-239. PubMed ID: 27839933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Paraganglioma: not just an extra-adrenal pheochromocytoma.
    Laird AM; Gauger PG; Doherty GM; Miller BS
    Langenbecks Arch Surg; 2012 Feb; 397(2):247-53. PubMed ID: 22086065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
    Ayala-Ramirez M; Feng L; Johnson MM; Ejaz S; Habra MA; Rich T; Busaidy N; Cote GJ; Perrier N; Phan A; Patel S; Waguespack S; Jimenez C
    J Clin Endocrinol Metab; 2011 Mar; 96(3):717-25. PubMed ID: 21190975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma.
    Ayala-Ramirez M; Palmer JL; Hofmann MC; de la Cruz M; Moon BS; Waguespack SG; Habra MA; Jimenez C
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1492-7. PubMed ID: 23436918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra-adrenal paragangliomas: insights from the largest single-institutional experience.
    Ayala-Ramirez M; Feng L; Habra MA; Rich T; Dickson PV; Perrier N; Phan A; Waguespack S; Patel S; Jimenez C
    Cancer; 2012 Jun; 118(11):2804-12. PubMed ID: 22006217
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of pathological grading systems for predicting metastatic potential in pheochromocytoma and paraganglioma.
    Koh JM; Ahn SH; Kim H; Kim BJ; Sung TY; Kim YH; Hong SJ; Song DE; Lee SH
    PLoS One; 2017; 12(11):e0187398. PubMed ID: 29117221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting Metastatic Potential in Pheochromocytoma and Paraganglioma: A Comparison of PASS and GAPP Scoring Systems.
    Wachtel H; Hutchens T; Baraban E; Schwartz LE; Montone K; Baloch Z; LiVolsi V; Krumeich L; Fraker DL; Nathanson KL; Cohen DL; Fishbein L
    J Clin Endocrinol Metab; 2020 Dec; 105(12):e4661-70. PubMed ID: 32877928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective application of the pathologic tumor-node-metastasis classification system for pheochromocytoma and abdominal paraganglioma in a well characterized cohort with long-term follow-up.
    Stenman A; Zedenius J; Juhlin CC
    Surgery; 2019 Nov; 166(5):901-906. PubMed ID: 31239074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response after surgical resection of metastatic pheochromocytoma and paraganglioma: can postoperative biochemical remission be predicted?
    Ellis RJ; Patel D; Prodanov T; Sadowski S; Nilubol N; Adams K; Steinberg SM; Pacak K; Kebebew E
    J Am Coll Surg; 2013 Sep; 217(3):489-96. PubMed ID: 23891076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimally invasive treatment of metastatic pheochromocytoma and paraganglioma: efficacy and safety of radiofrequency ablation and cryoablation therapy.
    McBride JF; Atwell TD; Charboneau WJ; Young WF; Wass TC; Callstrom MR
    J Vasc Interv Radiol; 2011 Sep; 22(9):1263-70. PubMed ID: 21856504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management and outcome of metastatic pheochromocytomas/paragangliomas: a monocentric experience.
    De Filpo G; Cantini G; Rastrelli G; Vannini G; Ercolino T; Luconi M; Mannelli M; Maggi M; Canu L
    J Endocrinol Invest; 2022 Jan; 45(1):149-157. PubMed ID: 34227051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodynamic instability during percutaneous ablation of extra-adrenal metastases of pheochromocytoma and paragangliomas: a case series.
    Deljou A; Kohlenberg JD; Weingarten TN; Bancos I; Young WF; Schroeder DR; Martin DP; Sprung J
    BMC Anesthesiol; 2018 Nov; 18(1):158. PubMed ID: 30400849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcome of a large series of patients surgically treated for pheochromocytoma.
    Khorram-Manesh A; Ahlman H; Nilsson O; Friberg P; Odén A; Stenström G; Hansson G; Stenquist O; Wängberg B; Tisell LE; Jansson S
    J Intern Med; 2005 Jul; 258(1):55-66. PubMed ID: 15953133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastases but not cardiovascular mortality reduces life expectancy following surgical resection of apparently benign pheochromocytoma.
    Timmers HJ; Brouwers FM; Hermus AR; Sweep FC; Verhofstad AA; Verbeek AL; Pacak K; Lenders JW
    Endocr Relat Cancer; 2008 Dec; 15(4):1127-33. PubMed ID: 18824558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma.
    Kong G; Grozinsky-Glasberg S; Hofman MS; Callahan J; Meirovitz A; Maimon O; Pattison DA; Gross DJ; Hicks RJ
    J Clin Endocrinol Metab; 2017 Sep; 102(9):3278-3287. PubMed ID: 28605448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perianesthetic risks and outcomes of pheochromocytoma and paraganglioma resection.
    Kinney MA; Warner ME; vanHeerden JA; Horlocker TT; Young WF; Schroeder DR; Maxson PM; Warner MA
    Anesth Analg; 2000 Nov; 91(5):1118-23. PubMed ID: 11049893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical outcome of laparoscopic surgery, including laparoendoscopic single-site surgery, for retroperitoneal paraganglioma compared with adrenal pheochromocytoma.
    Hattori S; Miyajima A; Hirasawa Y; Kikuchi E; Kurihara I; Miyashita K; Shibata H; Nakagawa K; Oya M
    J Endourol; 2014 Jun; 28(6):686-92. PubMed ID: 24499341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical Treatment of Malignant Pheochromocytoma and Paraganglioma: Retrospective Case Series.
    Strajina V; Dy BM; Farley DR; Richards ML; McKenzie TJ; Bible KC; Que FG; Nagorney DM; Young WF; Thompson GB
    Ann Surg Oncol; 2017 Jun; 24(6):1546-1550. PubMed ID: 28058556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.